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In recent years, evidence has been accumulated that metformin, an antidiabetic drug in the biguanide class, in addition to its
well-recognized glucose-lowering eﬀect, can also reduce cardiovascular mortality in the patients with type 2 diabetes mellitus
(T2DM). Besides, there are a few experimental studies on the possibility of the direct anti-ischemic eﬀect of the drug in both type
1 diabetes mellitus and T2DM. In our study, myocardial tolerance to ischemia in rats with neonatal streptozotocin T2DM was
investigated using the model of global ischemia-reperfusion of the isolated perfused heart. Metformin was administered i.p. at a
dose of 200mg/kg/day for 3 days prior to isolated heart perfusion. The results showed that both the infarct size and postischemic
recovery of left ventricular function were not diﬀerent between controls and metformin-treated animals. At the same time, the
infarctsizeintheT2DManimalswassigniﬁcantlylowerthanthatinthecontrols(24.4 ±7.6%versus45.0 ±10.4%,resp.,P<. 01),
indicative of the metabolic preconditioning in T2DM. It follows that the protocol of metformin administration used in this study
had not elicited cardioprotective eﬀect in animals with T2DM so that the diﬀerent mechanism(s) may underlie the beneﬁcial eﬀect
of metformin on cardiovascular complications in patients with T2DM which, however, would need further investigation.
1.Introduction
Ischemic heart disease (IHD) remains the leading cause of
death in the patients with type 2 diabetes mellitus (T2DM)
[1]. It seems apparent, therefore, that current pharmacother-
apy of the patients with both IHD and T2DM should be
aimed not only at glucose lowering but also at prevention
of cardiovascular complications. In recent years, evidence
has accumulated that metformin, the only antidiabetic drug
available for clinical use in the biguanide class, in addition
to its major glucose-lowering eﬀect, can also exert several
pleiotropic eﬀects including beneﬁcial changes in blood
rheology, serum lipid proﬁle, and putative anti-ischemic
eﬀects [2]. If this is the case, then metformin may have not a
single but multiple mechanisms of action in cardiovascular
disease, including cardio- and vasoprotection. This notion
might be further supported by the results of prospective
clinical trial UKPDS (United Kingdom Prospective Diabetes
Study) [3]. In that trial, the mortality rates in patients
with association of T2DM and excessive body weight were
compared between the group receiving metformin and that
receiving either sulfonylureas or insulin. The results showed
that metformin reduced all-cause mortality by 36% while
themortalitiesassociatedwithT2DM,myocardialinfarction,
andstrokewerealldecreasedby42,39,and41%,respectively.
Furthermore, the precise mechanism (or mechanisms) of2 Experimental Diabetes Research
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Figure 1: Left ventricular end-diastolic pressure (LVEDP) dynam-
ics in the course of the experiments.
biguanide-induced reduction of cardiovascular risk is still
poorly understood although some evidence is available
for vasoprotective eﬀect of metformin on the impaired
vascular reactivity in the rats with T2DM owing probably
to the increased activity of NO-synthase; antihypertensive
eﬀect of the drug was also demonstrated in spontaneously
hypertensiverats[4,5].Asfarasthecardioprotectiveeﬀectof
metformin is concerned, it had been found that the addition
of the drug to the perfusate resulted in the attenuation of
left ventricular postischemic dysfunction (stunning) in the
nondiabeticisolatedratheartmodel[6].Inthedistinctstudy
the infarct-limiting eﬀect of metformin was demonstrated in
mice with genetically determined T2DM after either single
intraperitoneal injection or intraventricular administration
during reperfusion [7]. Besides, regular oral administration
of metformin increased myocardial tolerance to ischemia in
animals with type I diabetes mellitus (T1DM) [8]. Molecular
mechanisms of the above ﬁndings are currently under
intense research. However, no information at all is available
as yet on the possible cardioprotective eﬀect of the repeated
parenteral treatment with metformin in the animals with
T2DM.
The present study is aimed at the analysis of the
protective eﬀect of the repeated treatment with metformin
on the global ischemia-reperfusion cardiac injury with use of
the neonatal streptozotocin-induced T2DM rat model.
2.MaterialsandMethods
All experiments were performed in accordance with the
“Guide for the Care and Use of Laboratory Animals”
(publication no. [NIH] 85-23).
2.1. Type 2 Diabetes Mellitus Model. The 3-4-day-old Wistar
albino rats were used throughout the experiments. The
model of streptozotocin-induced T2DM was used with i.p.
injection of streptozotocin dissolved in the citrate buﬀer (pH
= 5.5) at a dose of 65mg/kg as described previously in [9].
Control animals received the same volume of the vehicle
alone. The animals were grown on regular chow and water
available ad libitum.
2.2. Isolated Heart Perfusion. Detailed description of Lan-
gendorﬀ isolated heart perfusion technique is provided
elsewhere [10]. Brieﬂy, the 10–12 week old animals were
anesthetized with sodium pentobarbital (60mg/kg), and the
heart was excised via bilateral thoracotomy and perfused
through the ascending aorta with Krebs-Henseleit buﬀer at
the constant pressure of 85mmHg. The heart function was
stabilized for 15min followed by 30min global ischemia
ﬁnalized by 120min reperfusion. During the experiments,
left ventricular pressure was measured isovolumetrically
with use of polyethylene balloon connected to the pressure
transducer. The following parameters were monitored: left
ventricular end-diastolic pressure (LVEDP), left ventricular
developed pressure (LVDP), and heart rate (HR). Left
ventricular pressure signal was processed with custom-made
software. Besides, coronary ﬂow rate (CFR) was measured by
collection of perfusate outﬂow.
2.3. Experimental Protocol. T h ea n i m a l sw e r ea l l o c a t e dt o
four groups:
(1) controls (n = 13): nondiabetic rats treated with
intraperitoneal 0.9% sodium chloride solution injec-
tions for 3 days prior to the heart perfusion,
(2) controls+metformin(CM;n = 12):nondiabeticrats
treated with metformin (Nycomed, France) at a dose
of 200mg/kg i.p. for 3 days prior to the perfusion,
(3) T2DM (n = 12): the animals with T2DM treated
with intraperitoneal 0.9% sodium chloride solution
injections for 3 days prior to the heart perfusion,
(4) T2DM + metformin (T2DMM; n = 7): diabetic rats
treatedwithmetforminatadoseof200mg/kgi.p.for
3 days prior to the heart perfusion.
Hemodynamic parameters were registered at baseline,
that is, 15min before ischemia, immediately prior to
ischemia, at 10, 20, and 30min of ischemia, and at every
10min of reperfusion.
2.4.InfarctSizeDetermination. Attheendofreperfusion,the
hearts were rapidly cut into four equally spaced transverse
slices. The slices were immersed in 1% solution of 2,3,5-
triphenyltetrazolium chloride (TTC) for 15min at 37◦C.
TTC-stained slices were photographed with digital camera
Olimpus 2020 for further determination of TTC-negative
(necrotic) area. After computer planimetry (Photoshop CS),
the data were expressed as a ratio of necrotic area to the total
slice one.
2.5. Statistical Analysis. Statistical diﬀerences in hemody-
namic data, blood glucose concentration, and infarct sizeExperimental Diabetes Research 3
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Figure 2: Left ventricular developed pressure (LVDP) dynamics in
t h ec o u r s eo ft h ee x p e r i m e n t s .
area were evaluated with STATISTICA software (ANOVA,
Sheﬀe test). All data are presented as “mean ± standard devi-
ation”. The diﬀerences were considered signiﬁcant at P<. 05.
3. Results
3.1. Animal Body Weight and Blood Glucose Level. Regular
weighing and blood glucose determination with use of Accu-
Chek Performa glucometer (Roch, USA) were performed in
all animals before heart perfusion. Just prior to the heart
isolation, the control animals had an average weight of 187
± 32g compared to the signiﬁcantly lower value (145 ± 13g,
P<. 05) in the T2DM group. Blood glucose just prior to
the heart isolation in control, CM, T2DM, and T2DMM
groups was 6.4 ± 0.6, 5.8 ± 1.2, 9.5 ± 3.3 (P<. 05 versus
controls), and 8.2 ± 1.6mmol/l (P<. 05 versus controls),
respectively.Metformindidnotcausethesigniﬁcantdecrease
inbloodglucoselevelintheT2DMMgroup,possiblybecause
of relatively short duration of the treatment.
3.2. Cardiac Function. The baseline values of LVEDP,
LVDP, CFR, and HR did not diﬀer signiﬁcantly among
all groups (Figures 1, 2,a n d3, Table 1). As to the
dynamics, LVEDP increased to recover gradually with no
diﬀerencebetweengroupsthroughoutreperfusion.However,
there was a tendency towards lower values of LVEDP
during reperfusion in the groups T2DM and T2DMM
as compared to the controls. During reperfusion, LVDP
and CF decreased in all groups of animals, with no
signiﬁcant diﬀerence between groups. The group values
of HR during the experiments are shown in Table 1.
Both preischemic and postischemic diﬀerences in HR
within or between groups could be explained as due to
chance.
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Figure 3: Coronary ﬂow (CF) dynamics in the course of the
experiments.
3.3. Myocardial Infarct Size. Infarct size data are presented
in Figure 4. In controls, infarct size expressed in percent (see
above) averaged 45.0 ± 10.4%. Administration of metformin
to healthy animals did not cause the signiﬁcant change in
infarct size (55.6 ± 15.8%). At the same time, infarct size was
signiﬁcantly lower in the animals with T2DM in comparison
to the controls (24.4 ± 7.6%, P = .00017) while metformin
treatment had no appreciable eﬀect on this parameter in the
animals with T2DM (37.7 ± 8.3%).
4. Discussion
The results of the present study demonstrate that metformin
therapy at least with the dose used, route of administration,
and the duration of treatment had no cardioprotective eﬀect
in both intact and T2DM diabetic animals. Furthermore,
these data corroborate the concept of metabolic precondi-
tioning based on the still paradoxical increase of myocardial
tolerance to ischemia-reperfusion in the animals with both
T 1 D Ma n dT 2 D M[ 11].
The eﬀect of metformin on the in vivo myocardial
ischemia-reperfusion injury has been investigated by Calvert
etal.inintactmiceaswellasinthetransgenicT2DManimals
[7]. In this study, only a single administration of metformin
was used either 18 hours prior to ischemia or at the
very beginning of reperfusion. The authors have concluded
that metformin attenuated myocardial ischemic injury in
either protocol of drug administration with no eﬀect on
blood glucose concentration. In the diﬀerent study, the
acute cardioprotective eﬀect of a single metformin injection
in the left ventricular cavity either prior or after 12min
global cardiac ischemia was examined in the intact isolated
rat heart [6]. The authors demonstrated the signiﬁcant
improvement in coronary ﬂow rate and also stroke volume4 Experimental Diabetes Research
Table 1: Pre- and postischemic values of heart rate (HR, beats per minute) in diﬀerent groups.
Controls Controls + metformin T2DM T2DM + metformin
Preischemic HR, beats per min 239 ± 48 254 ± 33 251 ± 32 249 ± 32
Postischemic HR:
10min 219 ± 39 235 ± 74 203 ± 37 278 ± 90
20min 205 ± 34 252 ± 63 218 ± 22 286 ± 68
30min 210 ± 45 262 ± 71 239 ± 51 268 ± 80
40min 202 ± 59 268 ± 71 220 ± 34 270 ± 65
50min 193 ± 45 233 ± 56 214 ± 36 266 ± 75
60min 198 ± 50 249 ± 68 238 ± 39 269 ± 61
Controls CM T2DM T2DMM
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Figure 4: Infarct size data. Infarct size is signiﬁcantly lower in the
groups T2DM and T2DMM in comparison with the controls and
CM.
during postischemic period in metformin-treated group as
compared to the controls.
The beneﬁcial cardiovascular eﬀects of chronic
metformin administration were shown in the rats with
streptozotocin-induced T1DM; in particular, glucose-
lowering eﬀect and enhanced contractile response of the
myocardium to increased preload were both observed after
repeated oral treatment with metformin for 6 weeks [8]. In
contrast, chronic oral administration of metformin for one
month did not result in improved postischemic myocardial
contractility in the isolated hearts from Zucker diabetic
fatty rats [12] which is consistent with our ﬁndings. One
possible explanation for the lack of cardioprotective eﬀect
of metformin given systemically prior to the isolated heart
perfusion is drug washout which dramatically decreases
tissue drug concentration at the time of ischemia and
reperfusion. Suggestive of this, the more suitable models
for investigation of metformin-mediated cardioprotection
would be in vivo preparations or isolated heart experiments
with addition of the drug into the perfusion ﬂuid. Indeed,
metforminpretreatmentinrabbitssubjectedtotwotransient
intravascular coronary occlusions separated by one week
resulted in signiﬁcant infarct size limitation after second
period of ischemia [13].
Much less is known about the possible mechanisms of
cardioprotectiveeﬀectofthedrug.Thus,themajortherapeu-
tic eﬀects of metformin have been suggested to be because
of its ability to activate adenosine monophosphate-activated
protein kinase (AMPK) considered to be a common cellular
“energy sensor” activating the energy-sparing metabolic
processes resultant in the increased tolerance to hypoxia and
ischemia [14, 15]. Noteworthy, metformin has been found
to possess infarct-limiting eﬀect when administered during
reperfusion [7, 16]. This eﬀect was associated with increased
activation of AMPK, endothelial nitric oxide synthase, and
phosphatidylinositol 3-kinase, the latter being functionally
coupled to protein kinase B [16]. It seems that one of the
mostprobablemechanismsunderlyingmetformin-mediated
myocardial protection against ischemia-reperfusion injury
might include the prevention of mitochondrial permeability
transition pore opening in the initial stage of reperfu-
sion, which otherwise would lead to mitochondrial matrix
swelling, energy wasting, and induction of apoptosis [16].
In conclusion, the data obtained show that, despite
expectation, intraperitoneal treatment of diabetic rats with
metformin for 3 days did not result in any cardioprotec-
tive eﬀect. Most likely, the well-documented metformin-
mediated reduction of cardiovascular mortality in the
patients with T2DM is not directly related to the infarct
size limitation but to a diﬀerent mechanism, or mech-
anisms. Probably, such factors alone or in any combi-
nations as metformin-induced reduction in the progres-
sion of atherosclerosis because of increased expression of
antioxidant thioredoxin [17], attenuation of endothelial dys-
function [18], anti-inﬂammatory eﬀect [19], inhibition of
vascularsmoothmusclecellproliferation[20],anddecreased
expression of adhesion molecules on the endothelial cells
[21] may be involved. Further study with wide modiﬁcations
of the experimental protocol, for example, the duration
of ischemia, metformin dosage, schedule of metformin
administration, or distinct approaches, may be needed to
solve the issue.
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